Orchestra BioMed Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Two pivotal cardiovascular programs are advancing, with Virtue DEB offering a novel sirolimus-based delivery and AVIM therapy showing strong enrollment and immediate blood pressure benefits. Strategic partnerships have secured funding and minimized dilution, with AVIM commercialization targeted for 2028.
-
Two pivotal trials are underway for AVIM therapy and Virtue SAB, targeting large hypertension and coronary artery disease markets. Strong partnerships with Medtronic and Terumo, robust clinical data, and a royalty-based model position the company for significant growth, with key milestones expected by 2027.
Fiscal Year 2025
-
The company secured $150 million in strategic capital from Medtronic, Ligand, and Terumo, enabling progress on pivotal AVIM and Virtue trials. AVIM targets pacemaker patients with hypertension, with key data expected late next year, while Virtue leverages sirolimus for superior vascular outcomes.
-
Significant capital was raised through strategic partnerships, extending cash runway into late 2027 and supporting pivotal trials for AVIM Therapy and Virtue SAB. Both programs are advancing in large markets, with differentiated technology and strong clinical momentum. Key trial completions and data readouts are targeted for 2026 and 2027.
-
A partnership-driven model is enabling rapid advancement of two key programs: AVIM therapy with Medtronic, targeting hypertension in pacemaker patients, and Virtue SAB with Terumo, a novel drug-eluting balloon for coronary disease. Both programs show strong clinical promise and commercial potential, with pivotal studies underway and strategic partners handling commercialization.
-
The company leverages strategic partnerships to commercialize AVIM therapy for hypertension and Virtue Sirolimus Angio-Infusion Balloon for artery disease, both with strong clinical data and FDA Breakthrough Device Designation. AVIM is ahead in development, targeting commercialization by 2028.
-
Key device therapies for hypertension and coronary disease are advancing through pivotal trials, supported by strong partnerships and recent FDA breakthrough and IDE approvals. Expanded patient eligibility and favorable regulatory interactions position both programs for broader market impact and potential revenue growth.
-
A partnership-driven model advances two lead med tech programs: AVIM Therapy for hypertension, now in pivotal trials with Medtronic, and Virtue Sirolimus AngioInfusion Balloon, set for a head-to-head study against Boston Scientific's Agent Balloon with Terumo. Both programs show strong clinical data and significant market potential.
Fiscal Year 2024
-
Strategic partnerships with major med device firms drive product development and commercialization, focusing on capital efficiency and shared revenue. Flagship programs AVIM and Virtue are advancing through pivotal trials, with strong clinical data and a solid financial position supporting growth.
-
A partnership-driven MedTech model is enabling late-stage innovation and capital efficiency, with AVIM therapy showing strong clinical results and significant market potential through a Medtronic alliance. Virtue's sirolimus delivery platform is positioned to outperform competitors as it advances toward pivotal trials.